Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

SELL
$0.53 - $1.14 $2,862 - $6,155
-5,400 Reduced 3.0%
174,600 $106,000
Q3 2023

Nov 14, 2023

SELL
$0.84 - $1.43 $100,044 - $170,313
-119,100 Reduced 39.82%
180,000 $211,000
Q2 2023

Aug 11, 2023

SELL
$0.83 - $1.12 $8,397 - $11,331
-10,117 Reduced 3.27%
299,100 $265,000
Q1 2023

May 12, 2023

SELL
$0.91 - $1.69 $21,781 - $40,451
-23,936 Reduced 7.18%
309,217 $318,000
Q4 2022

Feb 13, 2023

SELL
$1.09 - $2.04 $50,082 - $93,731
-45,947 Reduced 12.12%
333,153 $420,000
Q3 2022

Nov 14, 2022

BUY
$1.55 - $3.01 $201,965 - $392,203
130,300 Added 52.37%
379,100 $610,000
Q2 2022

Aug 12, 2022

BUY
$1.39 - $3.12 $20,572 - $46,176
14,800 Added 6.32%
248,800 $490,000
Q1 2022

May 13, 2022

BUY
$2.6 - $4.17 $228,818 - $366,989
88,007 Added 60.28%
234,000 $711,000
Q4 2021

Feb 11, 2022

BUY
$3.64 - $7.78 $531,414 - $1.14 Million
145,993 New
145,993 $531,000
Q3 2020

Nov 13, 2020

SELL
$9.94 - $16.59 $896,588 - $1.5 Million
-90,200 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$12.07 - $19.34 $439,516 - $704,246
36,414 Added 67.7%
90,200 $1.37 Million
Q1 2020

May 14, 2020

BUY
$12.5 - $22.04 $672,325 - $1.19 Million
53,786 New
53,786 $836,000

Others Institutions Holding FIXX

About Homology Medicines, Inc.


  • Ticker FIXX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 57,402,000
  • Description
  • Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nucleas...
More about FIXX
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.